CG Oncology, Inc. (CGON)
NASDAQ:CGON
Want to see CGON full AI Analyst Report?
Top Page
CG Oncology, Inc.
(NASDAQ:CGON)
Select Model
Select Model
Rating:58Neutral
Price Target:
$72.00
▼(-1.95% Downside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by mixed financial fundamentals: an exceptionally strong, low-debt balance sheet offsets heavy losses and accelerating cash burn. Technically, the stock has a constructive trend above key moving averages with neutral-to-positive momentum, while valuation metrics provided offer limited support. The CFO appointment is a modest positive corporate catalyst.
Positive Factors
Balance Sheet Strength
Extremely low leverage and sizable equity provide durable financial flexibility to fund late-stage development, BLA filing activities, and initial commercialization investments without immediate reliance on dilutive financing. This buffer materially reduces near-term solvency risk.
Negative Factors
High Cash Burn
Sustained, accelerating cash burn is a material structural constraint: the company will likely need external funding to complete commercialization. That ongoing drain increases dilution risk and forces active treasury management, impacting strategic optionality over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Extremely low leverage and sizable equity provide durable financial flexibility to fund late-stage development, BLA filing activities, and initial commercialization investments without immediate reliance on dilutive financing. This buffer materially reduces near-term solvency risk.
Read all positive factors
CG Oncology, Inc. (CGON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.70B
Dividend YieldN/A
Average Volume (3M)981.08K
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue Growth666.01%
EPS Growth-69.02%
CountryUS
Employees113
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.34
Shares Outstanding88,202,480
10 Day Avg. Volume1,043,112
30 Day Avg. Volume981,081
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.11K
Enterprise Value/Gross Profit-2.37K
Enterprise Value/Ebitda-28.49
Forecast
1Y Price Target
$90.47Price Target Upside23.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-2.72
Revenue Forecast (FY)$11.76M
CG Oncology, Inc. Business Overview & Revenue Model
Company Description
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in ...
How the Company Makes Money
As a clinical-stage company, CG Oncology does not have publicly established, recurring commercial product revenue. Its funding has primarily come from external financing such as equity issuances (including proceeds from its IPO and follow-on offer...
CG Oncology, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
86
Very Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.07M | 4.04M | 1.14M | 204.00K | 191.00K | 10.36M |
| Gross Profit | -2.38M | -607.00K | 1.14M | 204.00K | 176.00K | 10.35M |
| EBITDA | -197.98M | -159.55M | -114.63M | -55.43M | -35.23M | -12.38M |
| Net Income | -186.75M | -161.00M | -88.04M | -48.61M | -35.44M | -12.84M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 791.59M | 754.80M | 199.30M | 147.75M | 58.69M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 742.15M | 742.00M | 187.67M | 143.48M | 53.61M |
| Total Debt | 7.58M | 7.02M | 238.00K | 1.03M | 15.94M | 15.13M |
| Total Liabilities | 43.48M | 38.99M | 21.42M | 14.51M | 22.57M | 18.44M |
| Stockholders Equity | 1.09B | 752.60M | 733.38M | 184.79M | 125.18M | 40.25M |
Cash Flow | ||||||
| Free Cash Flow | -160.43M | -132.48M | -78.95M | -45.68M | -29.82M | -13.75M |
| Operating Cash Flow | -160.01M | -132.35M | -78.71M | -45.68M | -29.80M | -13.65M |
| Investing Cash Flow | -393.90M | -245.82M | -300.76M | -121.19M | -55.35M | -97.00K |
| Financing Cash Flow | 546.14M | 153.59M | 628.28M | 87.00M | 119.69M | 15.45M |
CG Oncology, Inc. Technical Analysis
Neutral
73.43
Price Trends
67.28
Negative
60.27
Positive
48.76
Positive
Market Momentum
-0.50
Positive
43.77
Neutral
22.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Neutral. The current price of 73.43 is above the 20-day moving average (MA) of 67.40, above the 50-day MA of 67.28, and above the 200-day MA of 48.76, indicating a neutral trend. The MACD of -0.50 indicates Positive momentum. The RSI at 43.77 is Neutral, neither overbought nor oversold. The STOCH value of 22.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CGON.
CG Oncology, Inc. Risk Analysis
CG Oncology, Inc. disclosed 82 risk factors in its most recent earnings report. CG Oncology, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CG Oncology, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $2.63B | -67.46 | -1.41% | ― | 95.29% | 98.21% | |
62 Neutral | $2.85B | -6.52 | -5.89% | ― | 157.97% | 86.11% | |
58 Neutral | $5.70B | -23.75 | -23.33% | ― | 666.01% | -69.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.60B | -7.50 | -13.96% | ― | 3118.14% | 55.95% | |
47 Neutral | $2.56B | -9.69 | -36.95% | ― | ― | -68.57% | |
45 Neutral | $5.57B | -6.66 | -83.29% | ― | ― | 0.01% |
* Healthcare Sector Average
CGON
CG Oncology, Inc.
64.25
38.81
152.56%
COGT
Cogent Biosciences
32.67
27.85
577.80%
IDYA
IDEAYA Biosciences
29.10
10.28
54.62%
ARQT
Arcutis Biotherapeutics
20.86
6.88
49.21%
BEAM
Beam Therapeutics
28.64
11.81
70.17%
IRON
Disc Medicine
66.82
19.45
41.06%
CG Oncology, Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
CG Oncology Appoints Veteran Jim DeTore as Chief Financial Officer
Positive
Apr 13, 2026
On April 13, 2026, CG Oncology, Inc. appointed veteran biotech finance executive Jim DeTore as its Chief Financial Officer, formalizing his role after serving as Interim Principal Financial and Accounting Officer since November 2025. DeTore brings...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.